[Initial experiences with "Oranienburg" slow-release theophylline in asthma therapy of children and adolescents].
Experiences in 50 patients show that Theophyllin retard Oranienburg (280 mg theophylline) could be used as an effective bronchospasmolytic drug on conditions of mono- and combination-therapy. Advantages of this preparation are improvement of the compliance and an undisturbed night-sleep in patients. However an optimum dosage is hardly maintained in children by the present dose of a single tablet of 280 theophylline content. The effectiveness in therapy of childhood asthma could be improved by stronger sustained release effect and different doses of tablets.
Sollich
V
V
Klinik für Kinderheilkunde, Medizinischen Akademie, Magdeburg.
Schuster
R
R
Thal
W
W
Köhler
E
E
Walther
H
H
D000293:Adolescent; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D013806:Theophylline / Q000008:administration & dosage* / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D013806:Theophylline
Erste Erfahrungen mit Theophyllin retard "Oranienburg" in der Asthmatherapie bei Kindern und Jugendlichen.